News and Media

2016/05/17 – Quantum Genomics granted two new U.S. patents covering lead product QGC001

17 May 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents (No. 9,340,497 and […]

2016/04/26 – Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure

26 April 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has obtained authorisations from ANSM (the French national drug and health products safety agency) and CPP (the French consumer […]

2016/04/14 – 2015 annual report : acceleration of clinical trials, secured financing and internationalisation in progress

14 April 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that its 2015 annual report is available and issues a report on the highlights from 2015 and the start of […]

2016/03/24 – Quantum Genomics raises €8.6 Million in U.S. and Europe

24 March 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has completed a private placement with U.S. institutional investors totalling €5.54 million. Directly following the […]